RxDoctor Payments Data

Glen Kesler, MD

Internal Medicine · Covington, LANPI 1427075423

Payments from drug & device makers

$983in general payments, 2019–2025

Across 38 payments — averaging $25.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$159
  • Novo Nordisk$156
  • AstraZeneca$122
  • Johnson & Johnson$61
  • AbbVie$57
  • CSL Behring$43
  • plus $384 from 20 others

What the payments were for

  • Food & beverage$983100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$983 in reported general payments places this provider in the 65th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$44,929
Medicare patients
220
Services billed
660

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide94$104,832
MounjaroTirzepatide55$65,233
JardianceEmpagliflozin44$33,835
EliquisApixaban40$24,730
TrulicityDulaglutide20$24,706
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$21,460
JanuviaSitagliptin Phosphate13$16,717
JanumetSitagliptin Phos/Metformin Hcl11$15,981
KerendiaFinerenone13$9,340
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog14$6,089
Janumet XrSitagliptin Phos/Metformin Hcl11$5,946
Lantus SolostarInsulin Glargine,hum.Rec.Anlog28$4,614
Levothyroxine Sodium491$4,083
Colchicine16$2,376
Rosuvastatin Calcium234$2,355

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$156$104,83294 claims
Lilly USA, LLCMounjaro, Trulicity$15$89,94075 claims
MerckJanuvia, Janumet, Janumet Xr$15$38,64435 claims
PfizerEliquis$34$24,73040 claims
GSKTrelegy Ellipta$32$21,46016 claims
BayerKerendia$159$9,34013 claims
AbbVieSynthroid$57$1,50117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Covington

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →